Loading
Proved that adding the immunotherapy blinatumomab to standard treatment saves lives even in patients whose leukaemia was already undetectable.
224 MRD-negative patients randomised. 3-year OS 85% vs 68% (HR 0.41, 95% CI 0.23-0.73); relapse-free survival 80% vs 64%. NEJM 2024. Basis for the June 2024 FDA approval of blinatumomab in consolidation regardless of MRD status; changed frontline adult ALL worldwide. Benefit persisted across age and MRD sensitivity.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
488 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 3 years (MRD-negative cohort)primary | Blinatumomab + chemotherapy | 112 | 85% | 0.41 (0.23 to 0.73) | 0.002 | link |
| Chemotherapy | 112 | 68% | ||||
| Relapse-free survival at 3 years | Blinatumomab + chemotherapy | - | 80% | - | - | link |
| Chemotherapy | - | 64% |
Shares Blinatumomab added to frontline chemotherapy, ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Standard-risk B-cell acute lymphoblastic leukaemia in children, Blinatumomab.
Shares ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, CD19, T-cell engagers (bispecific).
Shares Blinatumomab added to frontline chemotherapy, Standard-risk B-cell acute lymphoblastic leukaemia in children, Blinatumomab, CD3.
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific).
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific).
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific).
Shares CD3, CD19, T-cell engagers (bispecific).
Shares Blinatumomab, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.